CYTK News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

CY

Mkt Cap

$8.61B

Volume

861.66K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026Cytokinetics announced four presentations at the Heart Failure Society of America Annual Scientific Meeting in October 2026, including two late-breaking clinical research presentations on aficamten (MYQORZO) for hypertrophic cardiomyopathy. The company plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026 following positive Phase 3 trial results.GlobeNewswire Inc. · Oct 2, 2026

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.The Motley Fool · Sep 18, 2026

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.Zacks Investment Research · Sep 4, 2026

Cytokinetics to Participate in September Investor ConferencesCytokinetics announced that management will participate in multiple investor conferences in September 2026. The company highlighted positive results from its ACACIA-HCM Phase 3 clinical trial for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), with plans to submit a Supplemental New Drug Application in Q4 2026. The trial demonstrated statistically significant improvements in both patient-reported and physician-assessed endpoints.GlobeNewswire Inc. · Sep 2, 2026

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?Cytokinetics announced additional positive results from ACACIA-HCM and MAPLE-HCM studies showing aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients, and outperformed metoprolol in obstructive HCM. The company plans to file for nHCM approval in Q4 2026, potentially expanding the drug's addressable market. Myqorzo received FDA approval in December 2025 for obstructive HCM treatment.Zacks Investment Research · Sep 2, 2026

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026Cytokinetics presented additional clinical trial results for aficamten (MYQORZO) at the ESC Congress 2026. ACACIA-HCM data showed aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients beyond exercise capacity improvements. MAPLE-HCM analysis demonstrated aficamten outperformed metoprolol across different pre-trial treatment groups in obstructive HCM patients. The company plans to submit a Supplemental New Drug Application for non-obstructive HCM in Q4 2026.GlobeNewswire Inc. · Aug 29, 2026

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700Cytokinetics CEO Robert Blum exercised 7,500 stock options at a strike price of $10.60 and sold them at a weighted-average price of $76.76, generating $575,700. Despite the sale, Blum retains substantial equity holdings of 377,820 direct shares and 4,166 indirect shares, indicating continued alignment with shareholders. Analysts view the transaction as routine profit-taking given the stock's 100% gain over the past 12 months, with 91% of analysts rating the stock a buy and a median price target of $107.50.The Motley Fool · Aug 22, 2026

Cytokinetics to Announce Second Quarter Results on August 6, 2026Cytokinetics announced it will report second quarter 2026 results on August 6, 2026, followed by a conference call at 4:30 PM ET. The company highlighted positive topline results from its ACACIA-HCM Phase 3 trial of aficamten in non-obstructive hypertrophic cardiomyopathy patients and plans to discuss findings with regulatory authorities.GlobeNewswire Inc. · Jul 23, 2026

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%Cytokinetics CEO Robert Blum sold 7,500 shares at $82.02 per share after exercising options at $10.60, generating $615,150 in proceeds. The sale represents only 2% of his total equity holdings, with the CEO retaining 381,986 shares and 186,745 options. The transaction appears to be routine diversification following the company's successful MYQORZO drug launch, which generated $4.8 million in first-quarter revenue and has been prescribed to approximately 680 patients by over 275 doctors.The Motley Fool · Jul 14, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Cytokinetics granted stock options, restricted stock units (RSUs), and performance stock units (PSUs) to 12 newly hired employees as material inducements to employment. The grants include 24,784 stock options at $71.38 per share, 16,429 RSUs vesting over 3 years, and 2,242 PSUs tied to performance goals. The awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire Inc. · Jun 17, 2026

CY

CYTKCytokinetics Inc.

CYTK

Pay with—

Available Balance0.00

Your PositionYou don't own any CYTK yet.

Related Tickers

Earnings